These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 35879887)

  • 1. Capturing the pool dilution effect in group testing regression: A Bayesian approach.
    Self S; McMahan C; Mokalled S
    Stat Med; 2022 Oct; 41(23):4682-4696. PubMed ID: 35879887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regression models for group testing data with pool dilution effects.
    McMahan CS; Tebbs JM; Bilder CR
    Biostatistics; 2013 Apr; 14(2):284-98. PubMed ID: 23197382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incorporating the dilution effect in group testing regression.
    Mokalled SC; McMahan CS; Tebbs JM; Andrew Brown D; Bilder CR
    Stat Med; 2021 May; 40(11):2540-2555. PubMed ID: 33598950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A general regression framework for group testing data, which incorporates pool dilution effects.
    Wang D; McMahan CS; Gallagher CM
    Stat Med; 2015 Nov; 34(27):3606-21. PubMed ID: 26173957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Group testing regression models with dilution submodels.
    Warasi MS; McMahan CS; Tebbs JM; Bilder CR
    Stat Med; 2017 Dec; 36(30):4860-4872. PubMed ID: 28856774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. One or two serological assay testing strategy for diagnosis of HBV and HCV infection? The use of predictive modelling.
    Parry JV; Easterbrook P; Sands AR
    BMC Infect Dis; 2017 Nov; 17(Suppl 1):705. PubMed ID: 29143611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From mixed effects modeling to spike and slab variable selection: A Bayesian regression model for group testing data.
    Joyner CN; McMahan CS; Tebbs JM; Bilder CR
    Biometrics; 2020 Sep; 76(3):913-923. PubMed ID: 31729015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bayesian regression for group testing data.
    McMahan CS; Tebbs JM; Hanson TE; Bilder CR
    Biometrics; 2017 Dec; 73(4):1443-1452. PubMed ID: 28405965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A methodology for deriving the sensitivity of pooled testing, based on viral load progression and pooling dilution.
    Nguyen NT; Aprahamian H; Bish EK; Bish DR
    J Transl Med; 2019 Aug; 17(1):252. PubMed ID: 31387586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adaptive elastic net for group testing.
    Gregory KB; Wang D; McMahan CS
    Biometrics; 2019 Mar; 75(1):13-23. PubMed ID: 30267535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal uses of pooled testing for COVID-19 incorporating imperfect test performance and pool dilution effect: An application to congregate settings in Los Angeles County.
    Nianogo RA; Emeruwa IO; Gounder P; Manuel V; Anderson NW; Kuo T; Inkelas M; Arah OA
    J Med Virol; 2021 Sep; 93(9):5396-5404. PubMed ID: 33930195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bayesian group testing with dilution effects.
    Tatsuoka C; Chen W; Lu X
    Biostatistics; 2023 Oct; 24(4):885-900. PubMed ID: 35403204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generalized additive regression for group testing data.
    Liu Y; McMahan CS; Tebbs JM; Gallagher CM; Bilder CR
    Biostatistics; 2021 Oct; 22(4):873-889. PubMed ID: 32061081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BAYESIAN GROUP TESTING WITH DILUTION EFFECTS.
    Tatsuoka C; Chen W; Lu X
    medRxiv; 2021 Dec; ():. PubMed ID: 33501464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial.
    Deckert A; Anders S; de Allegri M; Nguyen HT; Souares A; McMahon S; Boerner K; Meurer M; Herbst K; Sand M; Koeppel L; Siems T; Brugnara L; Brenner S; Burk R; Lou D; Kirrmaier D; Duan Y; Ovchinnikova S; Marx M; Kräusslich HG; Knop M; Bärnighausen T; Denkinger C
    Trials; 2021 Jan; 22(1):39. PubMed ID: 33419461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regression analysis for multiple-disease group testing data.
    Zhang B; Bilder CR; Tebbs JM
    Stat Med; 2013 Dec; 32(28):4954-66. PubMed ID: 23703944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pooled-testing procedures for screening high volume clinical specimens in heterogeneous populations.
    Bilder CR; Tebbs JM
    Stat Med; 2012 Nov; 31(27):3261-8. PubMed ID: 22415972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three-Stage Pooled Plasma Hepatitis C Virus RNA Testing for the Identification of Acute HCV Infections in At-Risk Populations.
    Sun HY; Chiang C; Huang SH; Guo WJ; Chuang YC; Huang YC; Yang CJ; Su LH; Chen YT; Chen YW; Hsu FC; Ho SY; Liu WC; Su YC; Chang SY; Hsiao CF; Hung CC; Yu ML
    Microbiol Spectr; 2022 Jun; 10(3):e0243721. PubMed ID: 35499354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bayesian inference on prevalence using a missing-data approach with simulation-based techniques: applications to HIV screening.
    Mendoza-Blanco JR; Tu XM; Iyengar S
    Stat Med; 1996 Oct; 15(20):2161-76. PubMed ID: 8910961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of lowering the screening and confirmation cutoff values for urine drug testing based on dilution indicators.
    Fraser AD; Zamecnik J
    Ther Drug Monit; 2003 Dec; 25(6):723-7. PubMed ID: 14639059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.